LEWISBURG, Tenn. — Marshall Medical Center (MMC) recently added Genius™ 3D Mammography™ developed by Hologic, Inc., to its range of imaging services, according to CEO Phyllis Brown.
Genius™ 3D exams use advanced breast imaging technology and are clinically proven to significantly increase the detection of breast cancers, while decreasing the number of women asked to return for additional testing.1-7
“We are pleased to continue enhancing the availability of advanced imaging technology at Marshall Medical Center,” said Brown. “This state-of-the-art imaging tool provides our technologists and radiologists with enhanced capability to identify breast cancer while reducing additional testing.”
The breast is a three-dimensional object composed of different structures located at different heights within the breast. These structures can overlap and cause confusion when viewed as a flat two-dimensional image. This is a leading reason why small breast cancers may be missed and normal tissue may appear abnormal, leading to unnecessary callbacks. A Genius exam uses breast tomosynthesis technology to create a three-dimensional image of the breast structure, which enables radiologists to more clearly see through overlapping tissue to detect cancers, often at an earlier stage.
A Genius exam includes both 2D and 3D images. During the 3D portion of the exam, an X-ray arm sweeps in a slight arc over the breast, taking multiple images. A computer then converts the images into a stack of thin layers, allowing the radiologist to review the breast tissue one layer at a time. A Genius exam requires no additional compression and takes just a few seconds longer than a conventional 2D breast cancer screening exam.
A Genius™ 3D Mammography™ exam is clinically proven to be a better option for women of all breast densities compared to 2D alone.1-2 Researchers have found that:
- The Genius™ 3D Mammography™ exam finds 20-65% more invasive breast cancers compared to 2D alone, an average increase of 41%.3
- Only the Genius™ 3D Mammography™ exam is FDA-approved as superior for women with dense breasts compared to 2D alone.1-2
- The Genius™ 3D Mammography™ exam reduces callbacks by up to 40% compared to 2D alone.2,4
In recent years, 3D technology has become a standard of care for mammography exams. Most insurance will cover a 3D exam; however, MMC offers patients their choice of either a conventional 2D or the Genius™ 3D exam. The 3D portion is affordably priced at $95 if not covered by insurance.
To schedule a mammogram at Marshall Medical Center, call 931.380.4044. Genius™ 3D Mammography™ is now available at the Maury Regional Women's Center in Columbia, Marshall Medical Center in Lewisburg and at Spring Hill Imaging Center in Spring Hill.
References:
1) FDA submissions P080003, P080003/S001, P080003/S004, P080003/S005
2) Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014 Jun 25;311(24):2499-507.
3) Results from Friedewald, SM, et al. "Breast cancer screening using tomosynthesis in combination with digital mammography." JAMA 311.24 (2014): 2499 2507; a multi-site (13), non-randomized, historical control study of 454,000 screening mammograms investigating the initial impact the introduction of the Hologic Selenia® Dimensions ® on screening outcomes. Individual results may vary. The study found an average 41% (95% CI: 20-65%) increase and that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1000 screening exams were found in women receiving combined 2D FFDM and 3D™ mammograms acquired with the Hologic 3D Mammography™ System versus women receiving 2D FFDM mammograms only.
4) Bernardi D, Macaskill P, Pellegrini M, et. al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 2016 Aug;17(8):1105-13.
5) Bernardi D, Macaskill P, Pellegrini M, et. al. Breast cancer screening with tomosynthesis(3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 2016 Aug;17(8):1105-13.
6) McDonald ES, Oustimov A, Weinstein SP, et al. Effectiveness of Digital Breast Tomosynthesis Compared With Digital Mammography: Outcomes Analysis From 3 Years of Breast Cancer Screening. JAMA Oncol. 2016 Jun 1;2(6):737-43.
7) Rafferty EA, Durand MA, Conant EF, et al Breast Cancer Screening Using Tomosynthesis and Digital Mammography in Dense and Nondense Breasts. JAMA. 2016 Apr 26;315(16):1784-6.